publication date: Oct. 3, 2014
A move by Genentech has eliminated discounts and rebates hospitals receive when they purchase three of the company’s top-selling infused cancer drugs.
Beginning Oct. 1, hospitals can now order Avastin (bevacizumab), Herceptin (trastuzumab) and Rituxan (rituximab) exclusively from six specialty distributors authorized by the drug maker.
Genentech said the move will bypass more than 80 full-line wholesale drug distribution centers, with the objective of enhancing efficiency and security of the supply chain for these widely used medications.
|Conversation with The Cancer Letter|
Scott Soefje: “These are Life-Saving Drugs. I’m Not Going To Stop Treating Patients, Right?”
The loss of discounts and rebates hospitals received for administering Genentech’s Avastin, Herceptin and Rituxan will increase costs to patients, said Scott Soefje, director of pharmacy at University Medical Center Brackenridge in Austin.
Fake Avastin, Paid for by Medicare, Administered to U.S. Patients
Two years ago, British authorities tested a shipment of chemotherapy drugs headed for North America.
They found that the agent, labeled as Genentech’s Avastin, contained no trace of Avastin’s active ingredient. The drugs were on the way to Canada, where they were to be sold to doctors throughout the U.S.
|Gonzalez-Angulo To Serve 10 Years In Poisoning Case|
Ana Maria Gonzalez-Angulo, a 43-year-old oncologist at MD Anderson Cancer Center, was sentenced to 10 years in prison for poisoning her lover and colleague George Blumenschein.
The sentence, issued Sept. 29, makes Gonzalez-Angulo ineligible for probation, but under Texas law, she will be eligible for parole in 5 years.
|FDA Publishes Two Guidances for Lab-Developed Tests|
FDA published two draft guidance documents Oct. 3 for regulatory oversight, notification and medical device reporting for laboratory developed tests.
|Groups Push for CMS Coverage for LDCT Lung Screening|
A coalition of patient advocacy and medical organizations urged the Centers for Medicare & Medicaid Services to cover low-dose computed tomography for Medicare patients at high risk for lung cancer.
NYC-based Research Alliance Offering $200,000 Per Year for Young Investigators
The Pershing Square Sohn Cancer Research Alliance is taking applications for its Prize for Young Investigators in Cancer Research. The prize of $200,000 per year for up to three years is awarded annually to five New York City-based scientists.
Leonidas Platanias named director of Lurie Comprehensive Cancer Center
Karmanos Cancer Institute and Wayne State sign new affiliation agreement
Robert Miller named medical director of ASCO Institute of Quality
MD Anderson Cancer Center receives $10 million from ExxonMobil
Jan Egberts appointed CEO of Agendia Inc.
Memorial Sloan Kettering to open largest suburban location
CancerCare receives $1.5 million from Susan G. Komen